Cytosorbents Corp
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
CTSO$5.80-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · Shares · Par value · Capital · Income (Loss) · Deficit · Equity | |||||||||||||||||
| | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2022 | 43,635,715 | | $43,635 | | $287,000,021 | | $2,329,195 | | $(253,997,878) | | $35,374,973 | ||||||
| Cumulative effect of adjustments to beginning balance | | — | | | — | | | 777,310 | | | — | | | (45,023) | | | 732,287 |
| Stock-based compensation (as restated) | — | | — | | 4,155,342 | | — | | — | | 4,155,342 | ||||||
| Proceeds from the exercise of stock options for cash, net of fees incurred | 84,905 | | 85 | | 218,193 | | — | | — | | 218,278 | ||||||
| Issuance of common stock offerings, net of fees incurred | | 10,389,554 | | | 10,390 | | | 14,245,542 | | | — | | | — | | | 14,255,932 |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | 130,091 | | 130 | | (209,094) | | — | | — | | (208,964) | ||||||
| Other comprehensive loss, foreign currency translation adjustment | — | | — | | — | | (1,799,874) | | — | | (1,799,874) | ||||||
| Net loss (as restated) | — | | — | | — | | — | | (29,246,760) | | (29,246,760) | ||||||
| Balance at December 31, 2023 (as restated) | 54,240,265 | | $54,240 | | $306,187,314 | | $529,321 | | $(283,289,661) | | $23,481,214 | ||||||
| Stock-based compensation | — | | — | | 3,759,534 | | — | | — | | 3,759,534 | ||||||
| Issuance of common stock offerings, net of fees incurred | | 382,823 | | | 385 | | | 178,269 | | | — | | | — | | | 178,654 |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | 207,058 | | 205 | | (7,115) | | — | | — | | (6,910) | ||||||
| Issuance of warrants | — | | — | | 690,709 | | — | | — | | 690,709 | ||||||
| Other comprehensive loss, foreign currency translation adjustment | — | | — | | — | | 3,722,692 | | — | | 3,722,692 | ||||||
| Net loss | — | | — | | — | | — | | (20,718,957) | | (20,718,957) | ||||||
| Balance at December 31, 2024 | 54,830,146 | | $54,830 | | $310,808,711 | | $4,252,013 | | $(304,008,618) | | $11,106,936 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.